← Product Code [CHI](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/CHI) · K970905 # SYNCHRON CX SYSTEMS LIPASE (LIPA) REAGENT (K970905) _Beckman Instruments, Inc. · CHI · Jun 4, 1997 · Clinical Chemistry · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/CHI/K970905 ## Device Facts - **Applicant:** Beckman Instruments, Inc. - **Product Code:** [CHI](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/CHI.md) - **Decision Date:** Jun 4, 1997 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 862.1465 - **Device Class:** Class 1 - **Review Panel:** Clinical Chemistry ## Indications for Use The SYNCHRON Systems Lipase (LIPA) Reagent, in conjunction with SYCNHRON Systems Lipase Calibrator, is intended for use in the quantitative determination of pancreatic lipase activity in serum or plasma samples. This assay is designed for use with clinical chemistry analyzers from Beckman Instruments, such as the SYCNRHON CX and LX Clinical Systems. ## Device Story Reagent kit for quantitative determination of pancreatic lipase activity in serum or plasma; used with Beckman SYNCHRON CX and LX clinical chemistry analyzers. System measures lipase activity via chemical reaction; incorporates ORDAC (over range detection and correction) feature to expand measuring range up to 1200 U/L. Operated by laboratory personnel in clinical settings. Output provides numerical lipase activity values; assists clinicians in diagnosing and monitoring pancreatic conditions like acute pancreatitis and duct obstruction. ## Clinical Evidence Bench testing only. Method comparison study (n=91) between LX and CX systems showed slope 1.068, intercept -0.42 U/L, and r=0.997. Linearity established from 5-600 U/L (default) and 480-1200 U/L (with ORDAC). Imprecision studies (n=80) demonstrated within-run CVs of 1.38-7.18% and total CVs of 2.24-9.77% across three levels. ## Technological Characteristics In vitro diagnostic reagent for lipase activity measurement. Utilizes enzymatic chemical reaction. Compatible with automated clinical chemistry analyzers (SYNCHRON CX/LX). Features ORDAC (over range detection and correction) for extended measuring range (up to 1200 U/L). ## Regulatory Identification A lipase test system is a device intended to measure the activity of the enzymes lipase in serum. Lipase measurements are used in diagnosis and treatment of diseases of the pancreas such as acute pancreatitis and obstruction of the pancreatic duct. ## Predicate Devices - Genzyme Lipase Reagent ([K952180](/device/K952180.md)) - SYNCHRON CX Clinical System ([K965240](/device/K965240.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} Beckman Instruments, Section 510(k) Notification SYNCHRON Systems Lipase Reagent Summary of Safety and Effectiveness K970905 1. **Submitted by:** Sheri Hall Product Submissions Manager Beckman Instruments, Inc. 200 S. Kraemer Blvd., W-337 Brea, California 92822-8000 Telephone: (714) 993-8916, FAX (714) 961-4457 JUN - 4 1997 2. **Date Submitted:** 3 March 1997 3. **Device Name(s):** SYNCHRON® Systems Lipase (LIPA) Reagent Lipase test system (21 CFR 862.1465) 4. **Predicate Device(s):** | | Predicate | Predicate Company | Docket Number | | --- | --- | --- | --- | | SYNCHRON CX Systems Lipase (LIPA) Reagent | Genzyme Lipase Reagent | Toyo Jozo Co., Ltd (Japan) | K952180 | | SYNCHRON LX Clinical System | SYNCHRON CX Clinical System | Beckman Instruments, Inc. | K965240 | 5. **Description:** This assay is designed for use with clinical chemistry analyzers from Beckman Instruments, such as the SYNCHRON CX® AND LX™ Clinical Systems. The SYNCHRON Systems Lipase (LIPA) Reagent, when used in conjunction with SYCNRHON Systems Lipase Calibrator, is intended for use in the quantitative determination of pancreatic lipase activity in serum or plasma samples. Lipase measurements are used in diagnosis and treatment of diseases of the pancreas such as acute pancreatitis and obstruction of the pancreatic duct. 6. **Intended Use:** The SYNCHRON Systems Lipase (LIPA) Reagent, in conjunction with SYCNHRON Systems Lipase Calibrator, is intended for use in the quantitative determination of pancreatic lipase activity in serum or plasma samples. This assay is designed for use with clinical chemistry analyzers from Beckman Instruments, such as the SYCNRHON CX and LX Clinical Systems. 7. **Comparison to the Predicate:** The SYNCHRON Systems Lipase (LIPA) Reagent is similar to the predicate in the intended use, chemical reaction, reagent components and packaging, measurement method, default measuring range, and calibration method. They differ in the SYCNHRON Systems Lipase Reagent uses the system ORDAC (over range detection and correction) feature to expand the measuring range to 1200 U/L. File: liason2.doc {1} Beckman Instruments, Section 510(k) Notification SYNCHRON Systems Lipase Reagent Summary of Safety and Effectiveness ## 8. Summary of Performance Data: The data in the Premarket Notification supports a finding of substantial equivalence to chemistry test systems already in commercial distribution. A summary of the data follows: ### Method Comparison | Reagent | Slope | Intercept (U/L) | r | n | Predicate Method | | --- | --- | --- | --- | --- | --- | | SYNCHRON Systems Lipase Reagent on the LX System | 1.068 | -0.42 | 0.997 | 91 | SYNCHRON Systems Lipase Reagent on the CX System | ### Linearity | Sample Type | Measuring Option | Measuring Range | Assessment | | --- | --- | --- | --- | | serum | default | 5 - 600 U/L | linear | | | ORDAC | 480 - 1200 U/L | linear | ### Imprecision | Sample | Mean (U/L) | S.D. (U/L) | %C.V. | n | | --- | --- | --- | --- | --- | | Within-Run Imprecision | | | | | | Level 1 | 109.53 | 1.51 | 1.38 | 80 | | Level 2 | 269.80 | 4.15 | 1.54 | 80 | | Level 3 | 16.33 | 1.17 | 7.18 | 80 | | Total Imprecision | | | | | | Level 1 | 109.53 | 2.50 | 2.28 | 80 | | Level 2 | 269.80 | 6.03 | 2.24 | 80 | | Level 3 | 16.33 | 1.59 | 9.77 | 80 | This summary of safety and effectiveness is being submitted in accordance with the requirements of the Safe Medical Device Act of 1990 and the implementing regulation 21 CFR 807.92. File: liemao2.doc {2} DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 2098 Gaither Road Rockville MD 20850 JUN - 4 1997 Sheri Hall - Manager, Premarket Regulatory Beckman Instruments, Inc. 200 S. Kraemer Boulevard, M/S W-337 P.O. Box 8000 Brea, California 92822-8000 Re: K970905 SYNCHRON® Systems Lipase (LIPA) Reagent Regulatory Class: II Product Code: CHI, JIT Dated: April 28, 1997 Received: May 2, 1997 Dear Ms. Hall: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. {3} Page 2 Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html". Sincerely yours, Steven I. Gutman Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4} page 1 of 1 510(k) Number (if known): Device Name: SYNCHRON® Systems Lipase (LIPA) Reagent Indications for Use: The SYNCHRON Systems Lipase (LIPA) Reagent, in conjunction with SYNCHRON® Systems Lipase Calibrator, is intended for use in the quantitative determination of pancreatic lipase activity in serum or plasma samples. This assay is designed for use with clinical chemistry analyzers from Beckman Instruments, such as the SYNCHRON CX® and LX™ Clinical Systems. 21 CFR § 862.1465 Lipase Test System (a) Identification. A lipase test system is a device intended to measure the activity of the enzyme lipase in serum. Lipase measurements are used in diagnosis and treatment of diseases of the pancreas such as acute pancreatitis and obstruction of the pancreatic duct. (b) Classification. Class I. (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign Off) Division of Clinical Laboratory Devices 510(k) Number 270905 Prescription Use ☑ (per 21 CFR 801.109) OR Over-the-Counter Use ☐ Optional Format 1-2-96 --- **Source:** [https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/CHI/K970905](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/CHI/K970905) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com